KR102114568B1 - 즉시 사용가능한 케토로락 제제 - Google Patents

즉시 사용가능한 케토로락 제제 Download PDF

Info

Publication number
KR102114568B1
KR102114568B1 KR1020187027505A KR20187027505A KR102114568B1 KR 102114568 B1 KR102114568 B1 KR 102114568B1 KR 1020187027505 A KR1020187027505 A KR 1020187027505A KR 20187027505 A KR20187027505 A KR 20187027505A KR 102114568 B1 KR102114568 B1 KR 102114568B1
Authority
KR
South Korea
Prior art keywords
composition
ketorolac
pharmaceutically acceptable
acceptable salt
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187027505A
Other languages
English (en)
Korean (ko)
Other versions
KR20180119610A (ko
Inventor
조셉 페르골리지
알렉산더 미로노프
차드 제임스 피켄즈
더글라스 자일스 존슨
Original Assignee
알티유 파머수티컬즈, 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알티유 파머수티컬즈, 엘엘시 filed Critical 알티유 파머수티컬즈, 엘엘시
Priority to KR1020207013936A priority Critical patent/KR102307601B1/ko
Publication of KR20180119610A publication Critical patent/KR20180119610A/ko
Application granted granted Critical
Publication of KR102114568B1 publication Critical patent/KR102114568B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187027505A 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제 Active KR102114568B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207013936A KR102307601B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40538410P 2010-10-21 2010-10-21
US61/405,384 2010-10-21
US201161481602P 2011-05-02 2011-05-02
US61/481,602 2011-05-02
PCT/US2011/057284 WO2012054831A2 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137009935A Division KR20140012029A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020207013936A Division KR102307601B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020197019855A Division KR20190085561A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Publications (2)

Publication Number Publication Date
KR20180119610A KR20180119610A (ko) 2018-11-02
KR102114568B1 true KR102114568B1 (ko) 2020-05-22

Family

ID=45973506

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207013936A Active KR102307601B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020137009935A Ceased KR20140012029A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020197019855A Ceased KR20190085561A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020187027505A Active KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020207013936A Active KR102307601B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020137009935A Ceased KR20140012029A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020197019855A Ceased KR20190085561A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Country Status (19)

Country Link
US (5) US9421191B2 (enExample)
EP (3) EP3632432B1 (enExample)
JP (1) JP6013346B2 (enExample)
KR (4) KR102307601B1 (enExample)
CN (2) CN108703948A (enExample)
CA (1) CA2814805C (enExample)
CY (1) CY1122516T1 (enExample)
DK (1) DK2616064T3 (enExample)
ES (2) ES2933198T3 (enExample)
HR (1) HRP20191994T1 (enExample)
HU (1) HUE045889T2 (enExample)
LT (1) LT2616064T (enExample)
MX (1) MX346879B (enExample)
PL (1) PL2616064T3 (enExample)
PT (1) PT2616064T (enExample)
RS (1) RS59526B1 (enExample)
SI (1) SI2616064T1 (enExample)
SM (1) SMT201900656T1 (enExample)
WO (1) WO2012054831A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
US10098872B1 (en) 2013-07-22 2018-10-16 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992485B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103830171B (zh) * 2014-03-04 2015-11-18 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP4008319B1 (en) * 2015-11-25 2024-11-20 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
FR3101917B1 (fr) 2019-10-09 2022-07-15 Ifp Energies Now Système de refroidissement à radiateur unique
CN110812325B (zh) * 2019-11-13 2022-04-05 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
CN119818450A (zh) * 2020-05-19 2025-04-15 南京海融医药科技股份有限公司 一种左酮咯酸的药物组合物及其制备方法
CN114159384B (zh) * 2021-02-07 2023-04-07 南京锐志生物医药有限公司 一种化学性质稳定的低刺激性酮咯酸氨丁三醇注射液
CN115518035B (zh) * 2021-06-24 2024-02-27 上海云晟研新生物科技有限公司 一种酮咯酸液体组合物、其制备方法及应用
CN113384524B (zh) * 2021-07-05 2025-08-12 四川尚锐生物医药有限公司 一种稳定的酮咯酸氨丁三醇注射液的制备方法
CN114191384A (zh) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂
CN114432240A (zh) * 2022-03-04 2022-05-06 郑州市中心医院 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
US6372755B2 (en) 1997-07-11 2002-04-16 Toray Industries, Inc. Stable medicinal compositions containing 4,5-epoxymorphinan derivatives
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
HRP20010780A2 (en) 1999-03-26 2002-12-31 Pozen Inc High potency dihydroergotamine compositions
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080317681A1 (en) * 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
CA2584184A1 (en) * 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
JP5189980B2 (ja) 2005-09-01 2013-04-24 バクスター・インターナショナル・インコーポレイテッド 可溶化剤として酸を含むアルガトロバン処方物
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
DOP2007000055A (es) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
KR20090040258A (ko) 2006-04-18 2009-04-23 이케이알 테라퓨틱스, 인코포레이티드 사전혼합된, 즉석용 약제 조성물
WO2007146795A2 (en) 2006-06-12 2007-12-21 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
CA2656087A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Sugar-free storage-stable antihistaminic syrups
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080057023A1 (en) 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
US7589106B2 (en) 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
KR100836624B1 (ko) 2006-12-08 2008-06-10 한국전자통신연구원 가변 고속 푸리에 변환 장치 및 그 방법
US20080312154A1 (en) * 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
WO2009064928A1 (en) 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TWI397038B (zh) * 2008-11-05 2013-05-21 Au Optronics Corp 使用半源極驅動架構之顯示面板及其顯示資料供應方法
JP6188021B2 (ja) * 2010-07-19 2017-08-30 バイオジェン チェサピーク エルエルシー グリブリドおよび他の薬剤の静脈内投与方法
AU2011281035B2 (en) 2010-07-21 2014-10-02 Cumberland Pharmaceuticals, Inc. Acetycysteine compositions and methods of use thereof
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration

Also Published As

Publication number Publication date
EP2616064A4 (en) 2016-07-20
DK2616064T3 (da) 2019-11-11
US10278959B2 (en) 2019-05-07
PT2616064T (pt) 2019-11-06
WO2012054831A3 (en) 2012-06-07
CA2814805A1 (en) 2012-04-26
EP2616064A2 (en) 2013-07-24
HRP20191994T1 (hr) 2020-02-07
SI2616064T1 (sl) 2019-12-31
MX2013004393A (es) 2014-09-12
MX346879B (es) 2017-04-03
EP3632432B1 (en) 2022-09-14
US20220023260A1 (en) 2022-01-27
KR102307601B1 (ko) 2021-09-30
CY1122516T1 (el) 2021-01-27
LT2616064T (lt) 2019-11-25
ES2933198T3 (es) 2023-02-02
US11116750B2 (en) 2021-09-14
PL2616064T3 (pl) 2020-02-28
US9421191B2 (en) 2016-08-23
CN108703948A (zh) 2018-10-26
US20180280351A1 (en) 2018-10-04
WO2012054831A2 (en) 2012-04-26
HUE045889T2 (hu) 2020-01-28
KR20140012029A (ko) 2014-01-29
EP3632432A1 (en) 2020-04-08
KR20190085561A (ko) 2019-07-18
JP6013346B2 (ja) 2016-10-25
ES2753981T3 (es) 2020-04-15
SMT201900656T1 (it) 2020-01-14
US9962371B2 (en) 2018-05-08
US20190105301A1 (en) 2019-04-11
CN103167800A (zh) 2013-06-19
EP2616064B1 (en) 2019-08-07
US20170007575A1 (en) 2017-01-12
US20120101142A1 (en) 2012-04-26
KR20180119610A (ko) 2018-11-02
CA2814805C (en) 2021-11-02
RS59526B1 (sr) 2019-12-31
JP2013543843A (ja) 2013-12-09
KR20200078541A (ko) 2020-07-01
EP4190327A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
KR102114568B1 (ko) 즉시 사용가능한 케토로락 제제
RU2362560C2 (ru) Фармацевтическая препаративная форма
TWI844703B (zh) 穩定的ast-3424注射液製劑及製備方法
CA2705733C (en) Reduced dose intravenous acetaminophen
AU2008216867B2 (en) Transoral dosage forms comprising sufentanil and naloxone
EP2683361B1 (en) Method for the preparaton of a levothyroxine solution
US20070209660A1 (en) Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same
AU2004268602A2 (en) Intranasal opioid compositions
JP2016529328A (ja) 舌下ブプレノルフィンスプレー
WO2016008546A1 (en) Aqueous formulation comprising paracetamol and ibuprofen
EP2377514A2 (en) Liquid parenteral formulation comprising a tramadol material and paracetamol
HK40026993A (en) Ready to use ketorolac formulations
HK40026993B (en) Ready to use ketorolac formulations
WO2014083071A1 (en) Injectable liquid formulation of the combination of tramadol and paracetamol
HK1262803A1 (en) Ready to use ketorolac formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180921

Application number text: 1020137009935

Filing date: 20130419

PA0201 Request for examination
PA0302 Request for accelerated examination

Patent event date: 20180921

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181029

Application number text: 1020137009935

Filing date: 20130419

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181206

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190619

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181206

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190709

Application number text: 1020137009935

Filing date: 20130419

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190619

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190507

Comment text: Amendment to Specification, etc.

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20191120

Patent event code: PE09021S02D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20200217

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200116

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190916

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190619

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190507

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200515

Application number text: 1020137009935

Filing date: 20130419

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200518

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200518

End annual number: 3

Start annual number: 1

PG1601 Publication of registration